Dr Catherine Mummery oversees novel therapeutics at the UCL Dementia Research Centre and is also a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery.

She is leading a world-first trial involving a ‘gene silencing’ drug (BIIB080) that has shown promise in safely and successfully lowering levels of the harmful tau protein known to cause Alzheimer's disease.

Alongside her work in finding new treatments, Dr Mummery is also working on a groundbreaking trial that would enable MRI scans to be completed in a fraction of the time they currently are.

Learn more about UCL's interdisciplinary approach to dementia here.